Novartis Pharmaceuticals holds down the fort on this side of the big pond. As the US pharmaceuticals marketing affiliate of Swiss drug giant Novartis AG, the company helps with the development and sales of its parent company's products in the US. Its product line addresses a range of ailments including cardiovascular and respiratory diseases, gastrointestinal complaints, central nervous system disorders, cancer and blood disorders, bone and joint conditions, and organ transplants. Key products include tumor growth inhibitor Gleevec, high blood pressure drug Diovan, and attention deficit disorder therapies Focalin and Ritalin.

Takeda San Diego develops high-throughput protein crystallography systems used to speed up the drug discovery process. The company's technology can detect the three-dimensional shape of proteins, an important step in determining how a drug can be attached to a protein to produce a therapeutic effect. The US biotech developer is one of Japanese drug maker Takeda's main research and development facilities. The subsidiary's drug discovery know-how is being used to develop new therapies for metabolic diseases such as diabetes, cancer, and inflammatory conditions.

Roxane Laboratories, a US-based subsidiary of Germany's Boehringer Ingelheim, oversees the development, manufacturing, and marketing of its parent company's multisource (generic) drugmaking business in the US. It sells about 75 medications in 250 package sizes, focusing on oral liquids, sustained-release and controlled-release tablets, cancer drugs, and nasal sprays. It also distributes narcotics, such as meperidine (generic Demerol) and methadone. Products developed and marketed by Roxane are manufactured by its sister company, Boehringer Inghelheim Roxane, also located in Columbus, Ohio.

Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland. Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of clinical-stage drug candidates for central nervous system disorders. Its product portfolio includes Iloperidone (oral), a compound for the treatment of schizophrenia completed Phase III clinical trial; and Tasimelteon, which completed Phase III clinical trials for transient insomnia and chronic primary insomnia. The company's products also comprise Iloperidone (Injectible) for the treatment of schizophrenia and Tasimelteon for the treatment of depression, which are in the Phase II initiation status.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Teva Pharmaceutical Industries Limited company was founded in 1901 and is headquartered in Petach Tikva, Israel. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease and respiratory products. Teva’s active pharmaceutical ingredient business provides vertical integration to Teva’s own pharmaceutical production and sells to third party manufacturers. The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

Tekmira Pharmaceuticals is giving diseases the silent treatment. The biopharmaceutical company is attempting to develop therapies that inhibit or "silence" certain disease-causing genes through ribonucleic acid interference (RNAi), a mechanism that disrupts the production of proteins that can lead to cancer, metabolic, and infectious diseases. Tekmira's lead candidates are being developed to treat tumors and high cholesterol. It also partners with other pharmaceutical companies, such as Alnylam Pharmaceuticals and Roche, to advance additional RNAi products using Tekmira's stable nucleic acid-lipid particles (SNALP) RNAi drug delivery technology.

Dyadic International, Inc. (Dyadic) is an early-stage biotechnology company. The Company has operations in the United States, the Netherlands and Poland. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies and the sale of its enzymes. The Company is a holding company that holds all of Dyadic International (USA), Inc. (Dyadic-Florida). Dyadic-Florida owns all of Geneva Investment Holdings Limited, Dyadic Nederland BV, and Dyadic International Sp. z o.o. Dyadic’s R&D activities focus on its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

Forbes Medi-Tech has an answer for folks wanting to lower their cholesterol by changing their diet. The firm makes Reducol, a dietary supplement ingredient that reduces LDL, the "bad" cholesterol associated with increased risk of heart disease. It sells the ingredient to food and nutritionals companies that incorporate it into their products. Pharmavite uses Reducol in its Cholest-Off supplement, and foodmakers in Europe use it in items such as yogurt, milk, and bread. Until 2008 Forbes Medi-Tech also had a drug development operation, which was testing pharmaceutical candidates to treat high cholesterol and metabolic conditions; however, it has divested those operations to focus on its Reducol business.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.